Skip to main content
Clinical Trials/IRCT20200128046294N1
IRCT20200128046294N1
Not yet recruiting
Phase 3

A Prospective Randomized Controlled Trial Comparing Three Advanced Therapies in the Treatment of Non-Alcoholic Steatohepatitis

Dr. Abidi Pharmaceuticals0 sites105 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr. Abidi Pharmaceuticals
Enrollment
105
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr. Abidi Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

  • Is a candidate for general anesthesia
  • Is eligible for bariatric surgery (SG)
  • Is \=18 and \=65 years old
  • Have a BMI \=30 and \=45 kg/m2
  • Have a platelet count \>150,000 and International Normalized Ratio (INR) \=1\.2
  • Have appropriate composite entry criteria on liver biopsy: NAFLD with activity score between 4 and 8, presence of hepatocyte ballooning, and fibrosis stage between 1 and 3, confirmed by independent reviews by 3 liver pathologists. In case of any discrepancies in histopathologic report, a joint review by 3 study pathologists will be performed.
  • Have the ability and willingness to participate in the study and agree to any of the arms involved in the study.
  • Able to understand the options and to comply with the requirements of each arm.
  • Have a negative urine pregnancy test at screening and randomization visits for women of childbearing potential.
  • Women, of childbearing age, must agree to use reliable method of contraception for 1 year.

Exclusion Criteria

  • 1\.Known history of other chronic liver diseases (drug induced, viral hepatitis, autoimmune, and genetic): a.Hepatitis B as detected by presence of hepatitis B surface antigen (HBsAg), b.Hepatitis C as detected by presence of hepatitis C virus (HCV) RNA, c.Autoimmune liver disease as diagnosed by antibodies and compatible liver histology, d.Primary biliary cirrhosis as defined by the presence of at least 2 criteria (elevated alkaline phosphatase, presence of anti\-mitochondrial antibody, and histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts), e.Primary sclerosing cholangitis, f.Wilson’s disease as diagnosed by low ceruloplasmin and compatible liver histology, g.Alpha\-1\-antitrypsin deficiency as diagnosed by alpha1\-antitrypsin level and liver histology, h.Hemochromatosis as diagnosed by presence of 3\+ or 4\+ stainable iron on liver biopsy, i.Drug\-induced liver disease as diagnosed by medical history, j.Known bile duct obstruction, k.Suspected or proven liver cancer
  • Type 1 diabetes or autoimmune diabetes
  • Known cases of human immunodeficiency virus infection
  • Prior bariatric surgery of any kind
  • Prior complex foregut surgery including any esophageal and gastric surgeries, anti\-reflux procedures, splenectomy, biliary diversion, and trauma
  • Thoracic, abdominal, pelvic and/or obstetric\-gynecologic surgery within 6 months
  • Any other surgery requiring general anesthesia within 6 weeks prior to signing the consent
  • American Society of Anesthesiologists Class IV or V
  • History of solid organ transplant
  • Severe pulmonary disease defined as FEV1 \< 50% of predicted value

Outcomes

Primary Outcomes

Not specified

Similar Trials